

**Are your MRI contrast agents cost-effective?**

Learn more about generic Gadolinium-Based Contrast Agents.



**FRESENIUS  
KABI**

caring for life

**AJNR**

**New risks, new doses.**

J G Russell and R Fawcitt

*AJNR Am J Neuroradiol* 1992, 13 (3) 850-852

<http://www.ajnr.org/content/13/3/850.citation>

This information is current as  
of April 27, 2024.

### New Risks, New Doses

J. G. B. Russell<sup>1</sup> and R. Fawcitt<sup>1</sup>

Our perception of the risks of ionizing radiation has substantially increased over the last decade (1–3). This change has been required by study of the survivors of the atomic bombs dropped on Japan in 1945. The bomb survivors are the largest group combining exposure to substantial excess radiation, good dosimetry, and careful follow-up. Studies of this population dominate our assessment of the hazards of ionizing radiation, although numerous other studies of radiation workers and other groups exposed to more than average radiation confirm (2) the estimates of the hazards derived from the studies of the bomb survivors. The increase in the assessed risk arises from two causes. First, the dosimetry of the bomb survivors; the estimates of the doses of ionizing radiation the survivors received have been downgraded by the new dosimetry (4) so the effect per unit dose is proportionately increased. Second, the longer follow-up discloses more fatal cancer cases than predicted earlier, and of a different pattern of primary site. In particular, a substantial excess number of gut fatal cancers have appeared than predicted earlier. This different pattern of the sites of origin of fatal cancers has in turn demanded an amendment (1) of the weighting factors used in calculating the effective dose. The term “effective dose” has replaced the old “effective dose equivalent” (1), and this allows distinction between doses calculated with the old weighting factors, and the new ones.

Table 1 gives the new and old (5) weighting factors. As can be seen, the organs in the head included in “remainder” are now weighted less heavily. Table 2 gives the new effective doses found for some examinations and indicates the variations when using the old and new weighting factors (6, 7). The effective dose estimates made by Feygelman et al in this issue of *AJNR* (8) were obtained using the old weighting factors: to obtain the current assessment of effective dose from their results requires a new computation, but

some estimates can be made bearing in mind Table 2. The fluoroscopy is likely to include the abdomen, thorax, and neck, as well as the head. Recomputed effective doses for this part of the examination are likely to show little change, and the parts of the examination involving the head will show a reduction of around 50%. This means that the recomputed effective doses for carotid angiography are likely to show a reduction, perhaps of around 20%, from the figures given by Feygelman et al. Applying the new weighting factors rather than the old ones has led to a reduction in the new effective dose in examinations of the head, but an examination using ionizing radiation involving the abdomen, eg, myelography, will be likely to show little change in the effective dose.

It must be stressed that Feygelman et al give a mean value for their hospital. They found in their small series a range of 23.4–2.7 mSv (uncorrected). Studies of different radiographic examinations show similar large variations in radiation dose (9). Any radiologist wishing to discuss risks of an examination should have available radiation doses assessed in his or her hospital.

An important factor in assessing risk is the age of the patient. Figure 1 indicates the variation in the risk of fatal cancer by age and sex from exposure of ionizing radiation at low doses and low dose rate (1). It should be noted that our perception of the probability coefficient for the development of fatal cancer as an average for the whole population increased from the 1977 estimate of 1.2% Sv<sup>-1</sup> (5) to 5% Sv<sup>-1</sup> now (1). The genetic injury risk also varies with age. It is estimated (1) at 1.3% Sv<sup>-1</sup> per child to be born. At birth, the risk of injury to future generations is about twice this (as about two children is the expectation for reproduction) and falls to zero as the expectation of parenting children falls to nothing.

---

<sup>1</sup> Department of Radiology, Royal Infirmary, Manchester, M13 0JH, United Kingdom.



TABLE 1: Organ weighting factors

	1977 (6)	1991 (1)
Red bone marrow	0.12	0.12
Bladder		0.05
Bone surface	0.03	0.001
Breast	0.15	0.05
Colon		0.12
Liver		0.05
Lung	0.12	0.12
Esophagus		0.05
Skin		0.01
Stomach		0.12
Thyroid	0.03	0.05
Gonads	0.25	0.20
Remainder	0.30	0.05

TABLE 2: Ratios of mean doses between 1991 and 1977 weighting factors, and current effective doses (6, 7)

	Effective Dose/ Effective Dose Equivalent	1991 1977	Typical Effective Dose (mSv)
Radiography			
Skull PA	0.31		0.2
Lateral	0.27		
Chest PA	0.92		0.05
Abdomen AP	1.8		1.4
Nuclear medicine			
Brain—Tc-99m gluconate	0.62		5
Computed tomography			
Head	0.5		1.8
Cervical spine	1.5		2.9
Chest	0.9		7.9
Abdomen	0.9		7.1
Lumbar spine	0.8		3.6
Pelvis	0.8		7.3

The possibility of radiation injury may be an important factor in deciding if ionizing radiation is to be used. An exposure of 10 mSv effective dose will carry a risk of promoting a fatal cancer of one case in 1000 examinations for a female teenager (perceived cancer risk  $10\% \text{ Sv}^{-1}$ ) or one case in 10,000 in a 70-year-old (perceived cancer risk  $1\% \text{ Sv}^{-1}$ ).

Costing the harm done by ionizing radiation in medicine can be assessed (10) and, in the United States, \$30,000/Sv (\$30/mSv) for an adult is a reasonable figure to use in this context, and five times this for children. More should be spent in a richer country, less in a poorer country, to avert exposure to ionizing radiation. It may be that the additional cost of magnetic resonance (11) imaging over other imaging techniques can be jus-




Fig. 1. The attributable lifetime risk from a single small dose at various ages at the time of exposure.

tified on purely financial grounds, by reason of the value of the averted ionizing radiation.

Feygelman et al (8) briefly discuss reducing the dose to the patient in cerebral angiography. It must be stressed that there are many more approaches available other than reducing screening time and field size. A recent review (12) noted 21 headings of methods of dose reduction. In this context, some of these may be stressed. Much of the dose arises from fluoroscopy. If an image intensifier is poorly adjusted, it may give a radiation dose four or more times than necessary (13). A quality assurance programme (14) is essential. The use of carbon fiber components (CFM) can allow substantial reductions (15)—for instance a CFM-faced grid with fiber interfaces can lead to a 20% reduction in dose for fluoroscopy and radiography. It must always be remembered also that if the use of ionizing radiation can be avoided, this will lead to a dose reduction of 100%, and if the dose to patient is reduced, the dose to staff is also reduced.

## References

1. International Commission on Radiological Protection (ICRP). 1990 Recommendations of the International Commission on Radiological Protection (ICRP Publication 60). *Ann ICRP* 1991;21:1-3
2. United Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR). Sources, effects and risks of ionizing radiation: 1988

- Report to General Assembly New York: United Nations, 1988
3. Committee on the Biological Effects of Ionizing Radiation. *Health effects of exposure to low levels of ionizing radiation (BEIRV)*. Washington, DC: National Academy of Press, 1990
  4. Fry RJM, Sinclair WK. New dosimetry of atomic bomb radiations. *Lancet* 1987;2:845-848
  5. International Commission on Radiological Protection (ICRP). Recommendations of the International Commission on Radiological Protection (ICRP Publication 26). *Ann ICRP* 1977;1:3
  6. Huda W, McLellan Y. How will the new definition of "effective dose" modify estimates of dose in diagnostic radiology? *J Radiol Prot* 1991; 11:241-247
  7. Shrimpton PC, Jones DG, Hillier MC, Wall BF, LeHeron JC, Faulkner K. *Survey of CT practice in the UK: dosimetric aspects*. National Radiation Protection Board R249. Didcot, 1991
  8. Feygelman VM, Huda W, Peters KR. Effective dose equivalents to patients undergoing cerebral arteriograms. *AJNR* 1992;13:845-849
  9. National Council on Radiation Protection and Measurements. Exposure of the U.S. population from diagnostic medical radiation (NCRP Report 100). *NCRP Rep* 1989
  10. Russell JGB, Webb GAM. Valuing the man-sievert in x-ray diagnosis. *Br J Radiol* 1987;60:681-684
  11. Evans RG, Evans RG Jr. Analysis of economics and use of MR imaging units in the United States in 1990. *AJR* 1991;157:603-7
  12. National Radiological Protection Board. *Patient dose reduction in diagnostic radiology*. London: Her Majesty's Stationery Office, 1990
  13. Poletti JL, Le Heron JC. Performance assessment of x-ray image intensified television fluoroscopy systems in New Zealand. *Br J Radiol* 1988;61:393-400
  14. National Council on Radiation Protection and Measurements. Quality assurance for diagnostic imaging equipment (NCRP Report 99). *NCRP Rep* 1988
  15. Hufton AP, Russell JGB. The use of carbon fibre material in table tops, cassette fronts and grid covers: magnitude of possible dose reduction. *Br J Radiol* 1986;59:157-163